 Receptors, Antigen, T-Cell
"Receptors, Antigen, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
| Descriptor ID |
D011948
|
| MeSH Number(s) |
D12.776.543.750.705.816.824
|
| Concept/Terms |
Receptors, Antigen, T-Cell- Receptors, Antigen, T-Cell
- T-Cell Antigen Receptor
- Antigen Receptor, T-Cell
- Receptor, T-Cell Antigen
- T Cell Antigen Receptor
- T-Cell Receptors
- Receptors, T-Cell
- T Cell Receptors
- T-Cell Receptor
- Receptor, T-Cell
- T Cell Receptor
- Receptors, T-Cell Antigen
- Receptors, T Cell Antigen
- T-Cell Antigen Receptors
- Antigen Receptors, T-Cell
- Antigen Receptors, T Cell
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Antigen, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Antigen, T-Cell".
- Receptors, Antigen, T-Cell
- Complementarity Determining Regions
- Receptor-CD3 Complex, Antigen, T-Cell
- Receptors, Antigen, T-Cell, alpha-beta
- Receptors, Antigen, T-Cell, gamma-delta
This graph shows the total number of publications written about "Receptors, Antigen, T-Cell" by people in this website by year, and whether "Receptors, Antigen, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 2 | 4 | | 1997 | 5 | 3 | 8 | | 1998 | 4 | 3 | 7 | | 1999 | 4 | 2 | 6 | | 2000 | 2 | 3 | 5 | | 2001 | 5 | 6 | 11 | | 2002 | 2 | 6 | 8 | | 2003 | 3 | 5 | 8 | | 2004 | 8 | 8 | 16 | | 2005 | 3 | 5 | 8 | | 2006 | 9 | 3 | 12 | | 2007 | 3 | 3 | 6 | | 2008 | 4 | 3 | 7 | | 2009 | 6 | 5 | 11 | | 2010 | 7 | 4 | 11 | | 2011 | 4 | 3 | 7 | | 2012 | 5 | 2 | 7 | | 2013 | 12 | 4 | 16 | | 2014 | 11 | 6 | 17 | | 2015 | 5 | 5 | 10 | | 2016 | 18 | 4 | 22 | | 2017 | 12 | 2 | 14 | | 2018 | 11 | 10 | 21 | | 2019 | 11 | 10 | 21 | | 2020 | 9 | 8 | 17 | | 2021 | 14 | 7 | 21 | | 2022 | 7 | 15 | 22 | | 2023 | 3 | 17 | 20 | | 2024 | 5 | 7 | 12 | | 2025 | 4 | 3 | 7 | | 2026 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Antigen, T-Cell" by people in Profiles.
-
Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N. Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. 2026 Jun 09; 10(11):3757-3768.
-
Magno JC, Guo J, Hall SC, Liu J, Albert GK, Carter JD, Davalos AS, Cao P, Bangar A, Drigot Z, Hudson H, Geluck T, Nevala WK, Markovic SN, Wilky BA, Davila E. Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer Res. 2026 Jun 01; 86(11):2688-2702.
-
Eken A, Johnson SA, Erdem S, Hsieh EWY. LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated. J Exp Med. 2026 May 04; 223(6).
-
Schultz L, McNerney K, Lamble AJ, Calkoen FG, Baruchel A, Ceppi F, Curran KJ, Gore L, Lamb M, Maude SL, Pulsipher MA, Qayed M, Ramakrishna S, Rheingold SR, Rossig C, Silbert SK, Steineck A, Summers C, Capitini CM, Bhojwani D, Gardner RA, Ghorashian S, Shah NN. The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2026 Apr; 23(4):260-278.
-
Landry LG, Wells KL, Anderson AM, Miller KR, Jones KL, Michels AW, Nakayama M. Quantitative V gene-targeted T cell receptor sequencing as a biomarker in type 1 diabetes. JCI Insight. 2026 Feb 09; 11(3).
-
Huey LM, Rosenzweig HL, Napier RJ. Resolving the field: a role for Nod2 in T cells. J Immunol. 2025 Dec 01; 214(12):3188-3198.
-
Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ. Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.
-
Naik S, Selukar S, Talleur AC, Deshpande S, Llaurador Caraballo G, Fabrizio VA, Rouce RH, Zeng XL, Vatsayan A, Rossoff J, Pacenta HL, John S, Phillips CL, Talano JA, Moskop A, Verneris MR, Myers GD, Hall E, Karras N, Bonifant CL, Qayed M, Bakinowski E, Keating AK, Baumeister SHC, Tomilson E, Hermiston ML, Satwani P, Krupski C, Chinnabhandar V, Stefanski HE, Egeler E, Curran KJ, Laetsch TW, Mackall CL, Prabhu S, Nguyen KP, Baggott C, Schultz LM, McNerney KO. Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
-
Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff JE, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras N, Baumeister SHC, Cooper SL, Hermiston M, Satwani P, Qayed M, Raikar SS, MacMillan M, Hall E, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy P, Schwartz MS, Ladha A, Yaghmour G, Kumaran MV, Bachanova V, Tracy S, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Shah BD, Muffly L, Faramand R. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025 Jun 10; 9(11):2763-2772.
-
Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch R, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared J, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik A, Hill BT, Kamdar MK, Ortiz-Maldonado V, Martinez-Cibrian N, Shune L, Shadman M. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun 05; 145(23):2762-2767.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|